Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: December 7, 2022

Details for Patent: 8,545,879

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,545,879 protect, and when does it expire?

Patent 8,545,879 protects QMIIZ ODT and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,545,879
Title:Fast disintegrating compositions of meloxicam
Abstract: The invention provides pharmaceutical compositions comprising a therapeutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical compositions are in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity. Also provided are processes for preparing a pharmaceutical composition of the invention. Further provided are methods of treating arthritis or pain in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a pharmaceutical composition according to the invention.
Inventor(s): Burns; David Allen (Wilmington, NC), Neal; Gregory Edward (Swindon, GB)
Assignee: Wilmington Pharmaceuticals, LLC (Wilmington, NC) R.P. Scherer Techonologies, Inc. (Somerset, NJ)
Application Number:12/988,919
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,545,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera QMIIZ ODT meloxicam TABLET, ORALLY DISINTEGRATING;ORAL 211210-001 Oct 19, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Tersera QMIIZ ODT meloxicam TABLET, ORALLY DISINTEGRATING;ORAL 211210-002 Oct 19, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,545,879

PCT Information
PCT FiledAugust 31, 2010PCT Application Number:PCT/US2010/047254
PCT Publication Date:March 03, 2011PCT Publication Number: WO2011/026080

International Family Members for US Patent 8,545,879

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2011026080 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.